Contributions
Abstract: EP1483
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Environmental factors
Background: Low levels of 25-hydroxyvitamin D (25-(OH)D) have been described as one of the possible environmental factors involved in multiple sclerosis (MS) etiopathogenesis.
Objectives: To analyse 25-(OH)D serum levels of MS patients from Madrid and Lanzarote, two regions of Spain with completely different UV radiation rates, and to correlate them with epidemiological data.
Methods: 60 RR-MS patients from Lanzarote and 538 RR-MS patients from Madrid were included in a prospective study of one year of follow-up. Serum samples were collected in such a way that we got 25-(OH)D serum levels data from every month of the year. Incidence in Lanzarote was assessed in MS patients according to McDonald criteria between 2008 and 2015, while prevalence date was 12/31/15. Epidemiological data from Madrid was identified by bibliographic searches.
Results: 25-(OH)D serum levels were significantly higher in Lanzarote than in Madrid (median: 30.94 vs 20.50 ng/ml, respectively; p=1.60e-76). This difference appears throughout the year, but it is more pronounced in the first semester of the year (p=1.69e-58) than in the second one (p=7.25e-28). Moreover, percentage of patients with 25-(OH)D< 20 ng/ml was significantly lower in Lanzarote than in Madrid, especially in the first semester of the year (p=7.75e-44). Age of disease onset was significantly higher in Lanzarote than in Madrid (p=0.04). In terms of epidemiology, prevalence in Lanzarote was 50/100000, and incidence was 2.5/100000 inhabitants. Meanwhile, for Madrid, prevalence and incidence, according to bibliography, would be approximately 100/100000 and 3.8/100000, respectively.
Conclusions: MS patients from Lanzarote showed significantly higher 25-(OH)D serum levels and later median age of disease onset than the ones from Madrid. Moreover, incidence and prevalence rates were lower for Lanzarote. However, further studies are required in order to elucidate whether UV radiation rates, 25-(OH)D serum levels or lifestyle could be responsible of the latitudinal gradient observed for MS.
Disclosure: S. Pérez-Pérez: nothing to disclose.
P. Eguia del Rio: reports honoraria for speaking, personal fees and non-financial support from Merck-Serono, Teva, Sanofi-Genzyme, Novartis and Biogen Idec; received honoraria for participating as investigator in a clinical trial from Roche.
M.I. Domínguez-Mozo: nothing to disclose.
M.A. García-Martínez: nothing to disclose.
M.F. Zapata-Ramos: nothing to disclose.
M.J. Torrejón: nothing to disclose.
R. Arroyo: received honoraria for speaking and participating as investigators in clinical trials and non-financial support from Merck-Serono, Teva, Sanofi-Aventis, Genzyme, Novartis, Biogen Idec, Roche and Bayer-Schering.
R. Álvarez-Lafuente: Reports grants and personal fees from Merck-Serono, personal fees and non-financial support from Biogen IDEC, grants, personal fees and non-financial support from Novartis Pharmaceuticals S.A., grants and personal fees from Genzyme, non-financial support from TEVA Pharma, S.L., non-financial support from Roche.
Abstract: EP1483
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Environmental factors
Background: Low levels of 25-hydroxyvitamin D (25-(OH)D) have been described as one of the possible environmental factors involved in multiple sclerosis (MS) etiopathogenesis.
Objectives: To analyse 25-(OH)D serum levels of MS patients from Madrid and Lanzarote, two regions of Spain with completely different UV radiation rates, and to correlate them with epidemiological data.
Methods: 60 RR-MS patients from Lanzarote and 538 RR-MS patients from Madrid were included in a prospective study of one year of follow-up. Serum samples were collected in such a way that we got 25-(OH)D serum levels data from every month of the year. Incidence in Lanzarote was assessed in MS patients according to McDonald criteria between 2008 and 2015, while prevalence date was 12/31/15. Epidemiological data from Madrid was identified by bibliographic searches.
Results: 25-(OH)D serum levels were significantly higher in Lanzarote than in Madrid (median: 30.94 vs 20.50 ng/ml, respectively; p=1.60e-76). This difference appears throughout the year, but it is more pronounced in the first semester of the year (p=1.69e-58) than in the second one (p=7.25e-28). Moreover, percentage of patients with 25-(OH)D< 20 ng/ml was significantly lower in Lanzarote than in Madrid, especially in the first semester of the year (p=7.75e-44). Age of disease onset was significantly higher in Lanzarote than in Madrid (p=0.04). In terms of epidemiology, prevalence in Lanzarote was 50/100000, and incidence was 2.5/100000 inhabitants. Meanwhile, for Madrid, prevalence and incidence, according to bibliography, would be approximately 100/100000 and 3.8/100000, respectively.
Conclusions: MS patients from Lanzarote showed significantly higher 25-(OH)D serum levels and later median age of disease onset than the ones from Madrid. Moreover, incidence and prevalence rates were lower for Lanzarote. However, further studies are required in order to elucidate whether UV radiation rates, 25-(OH)D serum levels or lifestyle could be responsible of the latitudinal gradient observed for MS.
Disclosure: S. Pérez-Pérez: nothing to disclose.
P. Eguia del Rio: reports honoraria for speaking, personal fees and non-financial support from Merck-Serono, Teva, Sanofi-Genzyme, Novartis and Biogen Idec; received honoraria for participating as investigator in a clinical trial from Roche.
M.I. Domínguez-Mozo: nothing to disclose.
M.A. García-Martínez: nothing to disclose.
M.F. Zapata-Ramos: nothing to disclose.
M.J. Torrejón: nothing to disclose.
R. Arroyo: received honoraria for speaking and participating as investigators in clinical trials and non-financial support from Merck-Serono, Teva, Sanofi-Aventis, Genzyme, Novartis, Biogen Idec, Roche and Bayer-Schering.
R. Álvarez-Lafuente: Reports grants and personal fees from Merck-Serono, personal fees and non-financial support from Biogen IDEC, grants, personal fees and non-financial support from Novartis Pharmaceuticals S.A., grants and personal fees from Genzyme, non-financial support from TEVA Pharma, S.L., non-financial support from Roche.